MIT scientists modified lipids used in experimental mRNA vaccines; the formulations remained stable for up to a year at room temperature and triggered immune responses in mice

MIT researchers have developed groundbreaking mRNA vaccines that remain effective at higher temperatures, ensuring better distribution, especially in regions lacking adequate ultra-low temperature storage. The use of AI technology has drastically ...

An mRNA lipid nanoparticle structure. Image credits: Wikimedia Commons

You may have experienced last-minute cancellations of your booster jab due to supply issues. Those disruptions often stem from the delicate nature of mRNA vaccines. To keep these vaccines stable, they must be transported in ultra-low temperature freezers across oceans and continents. Now, a team at MIT may have found a solution very quickly, using computer algorithms.

Using AI-based methods, the MIT engineers altered lipids (fat droplets) used to deliver the mRNA in vaccines to withstand high temperatures. The altered lipids were stable for up to a year at normal temperatures, or 2 months at nearly 100°F. When used in mice, vaccines based on these lipids triggered an immune response just as strong as those based on Moderna’s original vaccine, despite the high temperatures. The researchers also tested a microneedle-patch version of the vaccine that dissolves on the skin, potentially removing the need for a needle altogether: a detail introduced here so it isn’t a surprise later in the piece. The findings are documented in a September 2026 peer-reviewed study titled “Accelerated discovery of thermostable mRNA–lipid nanoparticle vaccines using data-efficient AI,” published in the journal Nature Biotechnology.

Why this matters


Although you may not think this issue affects you directly, many parts of the United States, including remote counties and pharmacies with unreliable ultra-low-temperature freezers, have struggled to distribute mRNA vaccines since 2021. If freezers break, deliveries are delayed, or a power cut strikes during hot weather, batches of vaccine can become unusable. Thermostable mRNA vaccines would primarily improve vaccine accessibility in areas without reliable electricity globally. At the same time, they would also improve the reliability of vaccine supply closer to home, for example, at the pharmacy a few blocks from your house.

A problem that has been brewing for years

Maintaining suitable storage conditions for mRNA vaccines has been a persistent challenge for years. In a 2022 study titled “Stability Modelling of mRNA Vaccine Quality Based on Temperature Monitoring throughout the Distribution Chain,” published in Pharmaceutics, models were made to predict the stability of mRNA vaccines. These models showed that stability becomes difficult to maintain, especially once vaccines have left well-developed countries. Problems with temperatures during transport are a common weakness in the current system, meaning that some people may have quicker access to protection than others.
ADVERTISEMENT

Image 2026-11-18 at 11
<p>Major delivery methods for mRNA vaccines explaining why LNPs are used at all. Image credits: Wikimedia Commons<br></p>
Not only could this new vaccine design be impactful, but it also shows how quickly progress can be made using AI. Typically, designing vaccines involves testing many combinations by hand, a process that can take months. In this case, though, MIT researchers worked alongside the university’s Computer Science and Artificial Intelligence Laboratory to build a computer algorithm that made intelligent predictions, narrowing down a viable formulation in just weeks. Rather than being used for flashy tasks such as generating images or essays, AI is proving valuable for speeding up tedious lab work that can otherwise take scientists years to complete.

Still to be proven

Although these results are very promising, it’s important to note that they have only been tested in mice (and, for the microneedle patches, in non-human primates). Before this vaccine can be given to humans, it must go through clinical trials, regulatory review, and mass production: stages that many promising results in mice have failed to reach. The microneedle-patch version mentioned above is even further from clinical use than the injectable vaccine itself. In reporting on the research, Reuters noted that, although promising, this research is by no means proven.

The wider implications
ADVERTISEMENT

If this research goes on to work in humans, it may reduce costs, simplify distribution, and mean that in the next pandemic, fewer people are disadvantaged by whether their local clinic has a reliable freezer. As we saw in real time during the recent pandemic, vaccine distribution has been a logistical struggle, and although this research could have wide benefits, it is not yet available. Keep an eye on this research, but don’t be too quick to forget how dependent the last pandemic’s vaccine rollout was on an unbroken cold chain.
Download
The Economic Times Business News App
for the Latest News in Business, Sensex, Stock Market Updates & More.
Download
The Economic Times News App
for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
READ MORE
ADVERTISEMENT

READ MORE:

LOGIN & CLAIM

50 TIMESPOINTS

More from our Partners

Loading next story
Business News › News › International › US News › MIT scientists modified lipids used in experimental mRNA vaccines; the formulations remained stable for up to a year at room temperature and triggered immune responses in mice
Text Size:AAA
Success
This article has been saved

*

+